Merck cholesterol pill enlicitide and cancer therapy sac-TMT tapped for new priority program FDA expects Merck to submit applications in April and autumn of 2026, documents show Both drugs if approved ...

The FDA has issued a supplemental biologics license application to teclistamab, a Johnson & Johnson therapy, to participate in its National Priority Voucher pilot program, according to Dec. 15 news ...

BOSTON, MA AND SAN FRANCISCO, CA / ACCESS Newswire / December 15, 2025 / Access Advance LLC and Via Licensing Alliance announced today Access Advance's acquisition of Via's HEVC/VVC program, a move ...

ROCHESTER, N.Y. — The Advance 2 Apprenticeship pre-apprenticeship program celebrated its first-ever graduating class Friday at the Finger Lakes Workforce Development Center. Fourteen people graduated ...

The FDA's priority review for Opdivo with AVD targets first-line treatment for stage 3 or 4 cHL in patients aged 12 and older. The phase 3 SWOG S1826 study supports the review, focusing on progression ...

MONTREAL, Dec. 10, 2025 /CNW/ - Novartis Canada is pleased to announce that Scemblix ® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding ...

The FDA has approved Augmentin XR, an oral antibacterial, under its Commissioner’s National Priority Voucher pilot program, marking the first approval granted through the expedited review pathway. The ...

Less than two weeks into his new role as Auburn's head football coach, Alex Golesh has a tremendous task ahead of him. AUBURN, Ala.-- A little over ten days into his tenure on the plains, new Auburn ...

The U.S. House of Representatives has given a unanimous thumbs-up to the Give Kids A Chance Act, which would revive the FDA’s rare pediatric review voucher program following its expiration in December ...

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having secured ultrafast drug reviews, questions and criticisms about the initiative ...

Two members of Congress launched an investigation into FDA Commissioner Marty Makary, MD, MPH, and his use of "priority vouchers" for expedited drug approvals, suggesting that the voucher program ...